![]() | |
Names | |
---|---|
Preferred IUPAC name
5-[3-(1-Methylcyclopropyl)propyl]-2H-pyrano[2,3-d]pyrimidine-2,4,7(1H,3H)-trione | |
Identifiers | |
CAS Number
|
|
3D model (JSmol)
|
|
ChEMBL |
|
ChemSpider |
|
DrugBank |
|
PubChem CID
|
|
UNII |
|
CompTox Dashboard (EPA)
|
|
InChI
| |
SMILES
| |
Properties | |
Chemical formula
|
C14H16N2O4 |
Molar mass | 276.292 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references
|
SCH 900271 is a nicotinic acid derivative designed to treat dyslipidemia. It reduced plasma free fatty acids levels, but without significant flushing, a side effect common with niacin that limits its usefulness. SCH 900271 is currently in human trials.[1]